Huayu Pharmaceuticals: The company's product, injectable cyclophosphamide, has obtained marketing approval in the UK.

Huayu Pharmaceuticals announced that its subsidiary SEACROSS PHARMACEUTICALS LIMITED has recently received approval from the UK Medicines and Healthcare products Regulatory Agency to market the company's product injection of Cyclophosphamide. Cyclophosphamide injection is mainly used to treat various types of cancer. The company has obtained marketing approval in several countries such as China, the UK, and Ireland, and the registration application is currently submitted in Germany. The UK marketing approval of this product will benefit the company by enriching its product pipeline in the international market, enhancing its market brand image, and continuously expanding the breadth and depth of its international business. However, due to factors such as the non-uniqueness of the product and competition from similar products, there is significant uncertainty as to whether it will generate significant revenue in the future. This does not have a significant impact on the company's operating performance in the short term.